Shanghai Yizhong Pharmaceutical Co Ltd (688091) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥21.03 Million ≈ $3.08 Million USD) by net assets (CN¥1.46 Billion ≈ $213.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Shanghai Yizhong Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Shanghai Yizhong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Shanghai Yizhong Pharmaceutical Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Yizhong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jefferson Capital, Inc. Common Stock
NASDAQ:JCAP
|
0.144x |
|
T1 Energy Inc.
NYSE:TE
|
0.410x |
|
Harbin Electric Coporation Jiamusi Electric Machine Co Ltd
SHE:000922
|
0.028x |
|
Beijing Shunxin Agriculture Co Ltd
SHE:000860
|
0.019x |
|
Beijing Cuiwei Tower Co Ltd
SHG:603123
|
-0.003x |
|
Shandong Denghai Seeds Co Ltd
SHE:002041
|
0.070x |
|
Suburban Propane Partners LP
NYSE:SPH
|
0.156x |
|
United States Steel Corp
BA:X
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Shanghai Yizhong Pharmaceutical Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.41 Billion ≈ $205.60 Million |
CN¥39.44 Million ≈ $5.77 Million |
0.028x | -52.50% |
| 2023-12-31 | CN¥1.46 Billion ≈ $214.35 Million |
CN¥86.55 Million ≈ $12.67 Million |
0.059x | -29.64% |
| 2022-12-31 | CN¥1.32 Billion ≈ $193.04 Million |
CN¥110.78 Million ≈ $16.21 Million |
0.084x | +302.36% |
| 2021-12-31 | CN¥1.18 Billion ≈ $172.02 Million |
CN¥-48.78 Million ≈ $-7.14 Million |
-0.041x | +50.00% |
| 2020-12-31 | CN¥243.51 Million ≈ $35.63 Million |
CN¥-20.21 Million ≈ $-2.96 Million |
-0.083x | +7.88% |
| 2019-12-31 | CN¥265.35 Million ≈ $38.83 Million |
CN¥-23.91 Million ≈ $-3.50 Million |
-0.090x | -78.92% |
| 2018-12-31 | CN¥212.18 Million ≈ $31.05 Million |
CN¥-10.68 Million ≈ $-1.56 Million |
-0.050x | +13.58% |
| 2017-12-31 | CN¥197.57 Million ≈ $28.91 Million |
CN¥-11.51 Million ≈ $-1.68 Million |
-0.058x | -- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more